Pfizer and BioNTech announced Monday their coronavirus vaccine was more than 90% effective in preventing COVID-19 among those without evidence of prior infection, hailing the development as “a great ...
Tuesday Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier. This is a 2-year study, where a subset of ...
The study will examine vaccine safety, efficacy and immunity at lower doses. Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical ...
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Pfizer vaccine fails to provide expected immunity for kids ages 2-5 in trials; Extra dose now tested
Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer has completed a Phase 1 trial titled “A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Dose ...
Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results